Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PSA Prostate Cancer Screening Does More Harm Than Good, USPSTF Concludes

This article was originally published in The Gray Sheet

Executive Summary

The final recommendations are a major shift in policy for the commonly performed blood test, and one certain to face ongoing controversy.


Related Content

CMS Issues List Of Potential National Coverage Determination Topics
Capitol Hill In Brief
New Products In Brief
AMA Delegates Dismayed With Prevention Task Force
Task Force’s PSA Proposal Prompts Calls For More Research On Prostate Cancer Diagnostics





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts